STAT3, which is another downstream effector of EGFR, has been recently reported to be preferentially activated in tumor-initiating cells/CSCs in claudin-low breast cancer [21], raising a possibility that it might, at least partially, mediate the downstream effects of EGFR on CSC properties of claudin-low cells. This evidence concerns the gene STAT3 and breast cancer.